- Home
- SUUN vs NTRB Comparison
SUUN vs NTRB Comparison
Compare SUUN & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- NTRB
- Stock Information
- Founded
- SUUN 2013
- NTRB 2016
- Country
- SUUN Canada
- NTRB United States
- Employees
- SUUN N/A
- NTRB N/A
- Industry
- SUUN
- NTRB Industrial Specialties
- Sector
- SUUN
- NTRB Health Care
- Exchange
- SUUN Nasdaq
- NTRB Nasdaq
- Market Cap
- SUUN 75.1M
- NTRB 71.8M
- IPO Year
- SUUN N/A
- NTRB N/A
- Fundamental
- Price
- SUUN $1.92
- NTRB $6.39
- Analyst Decision
- SUUN Strong Buy
- NTRB Buy
- Analyst Count
- SUUN 2
- NTRB 1
- Target Price
- SUUN $5.00
- NTRB $13.00
- AVG Volume (30 Days)
- SUUN 595.4K
- NTRB 36.9K
- Earning Date
- SUUN 09-30-2025
- NTRB 09-05-2025
- Dividend Yield
- SUUN N/A
- NTRB N/A
- EPS Growth
- SUUN N/A
- NTRB N/A
- EPS
- SUUN N/A
- NTRB N/A
- Revenue
- SUUN $25,798,969.00
- NTRB $2,398,437.00
- Revenue This Year
- SUUN N/A
- NTRB $560.75
- Revenue Next Year
- SUUN $46.21
- NTRB $588.39
- P/E Ratio
- SUUN N/A
- NTRB N/A
- Revenue Growth
- SUUN N/A
- NTRB 18.92
- 52 Week Low
- SUUN $1.23
- NTRB $2.98
- 52 Week High
- SUUN $6.43
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- SUUN 51.64
- NTRB 42.80
- Support Level
- SUUN $1.68
- NTRB $5.81
- Resistance Level
- SUUN $2.15
- NTRB $6.59
- Average True Range (ATR)
- SUUN 0.23
- NTRB 0.31
- MACD
- SUUN -0.04
- NTRB 0.05
- Stochastic Oscillator
- SUUN 27.59
- NTRB 66.74
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.